What Medilac-S Treats: Main Uses and Benefits

Medilac-S is used as supportive care to help manage a number of gastrointestinal symptoms and conditions, commonly alongside prescribed therapies. The core benefit of this product is to provide relief from digestive discomfort.

Clinical use generally focuses on managing symptoms associated with irritable bowel syndrome (IBS), acute gastritis, and providing support during treatment for conditions such as Helicobacter pylori or ulcerative colitis. Specifically, Medilac-S may be used to help ease gastrointestinal symptoms including diarrhea, constipation, dyspepsia, and bloating, which may occur following a course of antibiotics or other prescribed medications.

Supportive care is recognized as a component of comprehensive management strategies for certain digestive issues. When used as part of a treatment plan, this product may contribute to the patient's overall symptomatic relief.

---

Quick Fact: Relief for Digestive Discomfort

---

Regulatory References

1. https://medlineplus.gov/irritablebowelsyndrome.html

The official eligibility profile for the Probiotic Agent Medilac-S is strictly defined by regulatory requirements concerning patient populations and contraindications.

Absolute Contraindication

Use of Medilac-S is absolutely contraindicated in patients with a known severe hypersensitivity or allergy to the active substances (Bacillus subtilis or Enterococcus faecium) or to any of the product's excipients.

Age and Conditional Eligibility

Medilac-S is eligible for use across a wide age range, including adults, older adults, and the pediatric population, with authorized use established in patients as young as 0.1 years in certain regions. The medicine is authorized as an adjunct therapy for patient groups managing specific gastrointestinal conditions, such as Irritable Bowel Syndrome or Ulcerative Colitis, in regions with relevant marketing authorization.

Restrictions and Regulatory Caution

Use of live microbial products like Medilac-S is generally cautioned against in severely immunocompromised patients due to the theoretical risk of systemic infection. Furthermore, regulatory agencies have not approved any probiotic product as a drug for infants, and they caution against their use in preterm infants due to significant risks. An official regulatory statement on use during pregnancy and lactation is not explicitly documented in the available authoritative government literature.

Interactions with other medicines and products

The official regulatory interaction profile for Medilac-S, a live combined probiotic, is primarily structured around safeguarding the viability of its active ingredients, Bacillus subtilis and Enterococcus faecium. This product is not associated with documented pharmacokinetic interactions involving liver enzymes (CYP) or drug transporters, as it is not absorbed systemically.

---

Pharmacodynamic Interactions and Administration Restrictions

Interaction Type	Interacting Agent	Official Regulatory Statement
Antagonism	Antibiotics (Broad Class)	Co-administration may result in reduced efficacy of the probiotic, as the antibiotic can destroy the active live bacteria.
Antagonism	Antifungals (Broad Class)	May similarly prevent the probiotic from functioning well due to its anti-microbial properties.
Timing Constraint	Antibiotics	To mitigate antagonism, the probiotic must be administered at least 2 to 3 hours before or after the dose of the antibiotic.

---

Population-Specific Interaction Notes

While no formal chemical contraindications are documented, government health authorities note a population-specific interaction caution regarding use in certain patients. Immunosuppressed individuals, such as those receiving chemotherapy or those with HIV, have an officially documented increased risk of adverse effects from the live bacterial product. The regulatory context requires this specific safety constraint to be considered when the product is co-administered in this population.

Medilac-S is a probiotic formulation containing strains of Lactobacilli and Bifidobacteria. Its mechanism of action is mediated by direct and indirect interactions within the gastrointestinal lumen and with the intestinal epithelium and associated immune cells.

---

How Medilac-S Works

Medilac-S acts as a microbiome modulator and host cell signaler. Its components, including viable bacteria and secreted effector molecules (e.g., short-chain fatty acids (SCFAs), peptides), target several biological components.

• Epithelial Barrier Interaction: Bacterial components promote the expression of tight junction proteins (like zona occludens-1 and occludin) on intestinal epithelial cells (IECs), acting as barrier stabilizers. Pili on the cell surface facilitate adhesion to the mucosa.
• Intracellular Pathways: Effector molecules can inhibit the nuclear translocation of the transcription factor NF-kappaB in IECs and immune cells. This inhibition occurs through the stabilization of the NF-kappaB inhibitor, IkappaB, preventing its degradation.
• Downstream Cascades: The resultant suppression of NF-kappaB signaling downregulates the transcription of genes encoding pro-inflammatory cytokines (e.g., IL-8), modulating mucosal immune responses.
• System-Level Modulation: Bacterial metabolism, particularly the fermentation of non-digestible carbohydrates, yields SCFAs (primarily butyrate), which are agonists for receptors (e.g., GPR43) on enteroendocrine cells and colonocytes. Butyrate serves as an energy source for colonocytes and influences systemic physiology through the gut-immune axis, promoting intestinal homeostasis and localized immune tolerance.

Administration Instructions for Medilac-S

Medilac-S is an oral product containing the live bacterial strains Bacillus subtilis R0179 and Enterococcus faecium R0026 in capsule form. The following are the administration guidelines, typically used as an adjunct (additional) therapy:

---

Official Dosing and Timing

Guideline Element	Instruction
Route	Oral (taken by mouth)
Dose	Two capsules per dose.
Frequency	Three times daily (TID)
Timing	Administer the dose before meals

Procedural and Course Structure

1. Ingestion: Swallow two capsules whole with water.
2. Repetition: Repeat this dosage and timing schedule three times each day.
3. Preparation: No specific preparation, such as dilution or shaking, is generally required for the capsule formulation.
4. Duration: The course of administration is typically set for a duration of four weeks, though treatment periods may range from 1 to 12 weeks.

Age-Specific Use

The established dosage regimen is primarily established for adult patients. Specific, distinct dosing modifications for pediatric patients or other age groups are not explicitly defined in the core administration protocols.

---

Note on Missed Doses: Specific instructions on how to manage a missed dose (e.g., skip or take immediately) are not detailed in the general administration protocols. Patients should follow the instructions provided by their prescribing healthcare provider.

Medilac-S: Recent Clinical Evidence

---

Evidence for Use in Ulcerative Colitis (UC)

Research has examined the use of Medilac-S as an adjunctive treatment—meaning it was used alongside standard prescribed medications—for adults diagnosed with mild-to-moderate Ulcerative Colitis. Studies conducted include systematic reviews and meta-analyses of Randomized Controlled Trials (RCTs). These studies primarily focused on measuring the rate of achieving clinical remission and tracking changes in clinical indices. The findings contribute to the broader evidence landscape when combined with conventional treatments. However, results apply only to the populations studied, which were predominantly from a Chinese patient population, and the assessment periods were generally short-term (4 to 8 weeks). Long-term outcomes are not fully established.

---

Evidence for Use in Irritable Bowel Syndrome (IBS)

Medilac-S was evaluated in research exploring how symptoms change over time in conditions like Irritable Bowel Syndrome (IBS). Trials assessed the product’s use as an add-on to conventional care and monitored changes in global symptom scores and specific patient-reported outcomes describing perceived discomfort. The research describes patterns related to the overall observed change in symptoms. Similar to UC research, evidence is mainly drawn from studies conducted in a Chinese population, and there is limited information for long-term outcomes regarding sustained management.

---

Evidence for Gastrointestinal Symptoms Following Microbiota Disruption

The body of evidence for the product's use for acute changes in gastrointestinal function, such as symptoms associated with antibiotic-associated diarrhea (AAD) and constipation, reflects high consistency and weight. Large meta-analyses of RCTs have been applied, monitoring the incidence and duration of symptoms in patients receiving antibiotics. Research was also evaluated in short-term studies exploring changes in defecation frequency and stool consistency scores. The assessment periods for this research are typically short-term, aligned with acute management.

Key Studies & References

1. Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis
2. Live Combined Bacillus Subtilis and Enterococcus Faecium for the Treatment and Prevention of Antibiotic-Associated Diarrhea: A RCT-Based Meta-Analysis
3. Efficacy and safety of live combined Bacillus subtilis and Enterococcus faecium in patients with constipation: a meta-analysis of randomized controlled trials
4. Guidelines for the Evaluation of Probiotics in Food (Report of a Joint FAO/WHO Working Group)

Common questions about Medilac-S (FAQ)

Q: What is Medilac-S and how does it work?

Medilac-S is a probiotic supplement containing a specific blend of beneficial bacteria, including Lactobacillus acidophilus and Bifidobacterium longum. These organisms work by helping to restore and maintain the natural balance of microflora (good bacteria) in the gut. This balanced environment is crucial for proper digestion and overall gut health, especially after disturbances caused by illness, antibiotic use, or dietary changes.

Q: What are the main uses for Medilac-S?

Medilac-S is commonly used to support digestive health and maintain a healthy balance of gut bacteria (microflora). It may be recommended:

• To help prevent or manage diarrhea associated with taking antibiotics.
• To help ease symptoms of Irritable Bowel Syndrome (IBS), such as bloating and discomfort.
• To aid in restoring gut flora after episodes of infectious diarrhea.
• To provide general support for a healthy digestive system.

Q: How should I take Medilac-S?

Medilac-S is typically taken orally once or twice daily, or as recommended by a healthcare provider. The capsules or sachets can be taken with or without food. For best results, it is generally recommended to maintain a consistent schedule and take the product at the same time each day.

Q: Can I take Medilac-S with antibiotics?

Yes, you can. In fact, Medilac-S is often recommended to be taken alongside antibiotics. Antibiotics can disrupt the natural balance of the gut flora, leading to antibiotic-associated diarrhea. Taking Medilac-S can help to replenish the beneficial bacteria and reduce this side effect. However, to maximize the benefit, it is important to take Medilac-S at least 2 to 3 hours before or after your antibiotic dose.

Q: Does Medilac-S cause any side effects?

Medilac-S is generally well-tolerated. Since it introduces live organisms to the digestive tract, some people may initially experience mild digestive discomfort as their body adjusts. This can include:

• Slight bloating or gas.
• Mild stomach rumbling.

These side effects are usually temporary and diminish with continued use. If you experience severe or persistent side effects, discontinue use and consult a healthcare professional.

Q: Is Medilac-S suitable for children?

Medilac-S is available in formulations that are suitable for use in children. The dosage and specific formulation (e.g., powder for mixing with food or liquid) may differ from adult recommendations. It is essential to follow the dosing instructions provided on the product packaging for the pediatric formulation or as directed by a child’s pediatrician.

Q: How should I store Medilac-S?

Medilac-S contains live bacteria, and proper storage is crucial to maintain its effectiveness. It should be stored in a cool, dry place, away from direct heat and moisture. Many formulations may require refrigeration to ensure the viability of the probiotic cultures. Always check the product's packaging for specific temperature storage requirements.

Q: How long will it take for Medilac-S to work?

The time it takes for Medilac-S to have a noticeable effect can vary depending on the individual and the condition being treated. Some people may notice an improvement in digestive comfort within a few days, especially when treating antibiotic-associated diarrhea. For more chronic conditions like IBS support, it may take several weeks of consistent use to fully restore the gut flora balance and see optimal benefits.

Q: Are there any foods I should avoid while taking Medilac-S?

There are no specific foods that must be avoided while taking Medilac-S. However, consuming a diet that is rich in fiber (prebiotics) can help the probiotic bacteria thrive, potentially enhancing the supplement's effects. While taking it, it is best to avoid consuming extremely hot foods or drinks immediately alongside the capsule, as excessive heat can harm the live bacteria.

How to Store and Dispose of Medilac-S

Storage and disposal instructions for Medilac-S are defined by regulatory agencies to protect its stability as a product containing live microorganisms.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C in a cool place.
Protection	Must be protected from moisture and light.
Container	Keep the medicine in its original container and ensure it remains tightly closed.
Prohibition	Do not freeze the product, as this can compromise the active ingredients.

Handling and Disposal

The medicine must be stored out of the sight and reach of children.

Unused or expired Medilac-S must be disposed of in accordance with local regulatory requirements. To prevent environmental contamination, the product should not be disposed of into wastewater (e.g., flushed down the sink or toilet) unless explicitly directed by official government guidance.